Heat Biologics, Inc. (NASDAQ:HTBX) Files An 8-K Other EventsItem 8.01 Other Events.
On September 28, 2017, Heat Biologics, Inc. (the “Company”) issued a press release announcing the expected calendar for its previously disclosed intended rights offering to certain of the Company’s existing security holders.
Under the proposed rights offering, the Company will distribute non-transferable subscription rights to purchase shares of common stock to its eligible stockholders and participating warrant holders as of the record date. Holders who exercise their subscription rights in full will be entitled to subscribe for additional shares that are not purchased by other shareholders. The registration statement relating to the rights offering has been filed with the Securities and Exchange Commission but has not yet become effective.
The expected rights offering calendar is as follows:
Ownership Date:
Wednesday, Oct. 11, 2017 by 4 p.m. ET (NASDAQ closing bell)
Ex-Right Date:
Thursday, Oct. 12, 2017 (HTBX trades without the rights attached)
Record Date:
Friday, Oct. 13, 2017
The expected subscription period is as follows:
Beginning date:
Friday, Oct. 20, 2017
Ending date:
Wednesday, Nov. 8, 2017 by 5 p.m. ET
The press release is attached as Exhibit 99.1 to this Current Report on Form 8-K and is incorporated herein by reference.
Item 8.01Financial Statements and Exhibits.
The following exhibit is filed with this Current Report on Form 8-K:
|
Exhibit Number |
Description |
|
99.1 |
Press Release of Heat Biologics, Inc. dated September 28, 2017 |
HEAT BIOLOGICS, INC. ExhibitEX-99.1 2 htbx_ex99z1.htm PRESS RELEASE Press Release EXHIBIT 99.1 Heat Biologics Announces Expected Calendar for Rights Offering DURHAM,…To view the full exhibit click here
About Heat Biologics, Inc. (NASDAQ:HTBX)
Heat Biologics, Inc. is a development-stage company focused on developing allogeneic, off-the-shelf cellular therapeutic vaccines to combat a range of cancers. The Company is an immuno-oncology company, which focuses on T cell-stimulating platform technologies, such as Immune Pan-Antigen Cytotoxic Therapy (ImPACT) and Combination Pan-Antigen Cytotoxic Therapy (ComPACT). Using its ImPACT platform technology, the Company has developed HS-410 (vesigenurtacel-L) as a product candidate to treat non-muscle invasive bladder cancer (NMIBC), and HS-110 (viagenpumatucel-L), which is intended for use in combination with an anti-PD-1 checkpoint inhibitor, as a potential treatment for patients with non-small cell lung cancer (NSCLC). Using its ComPACT platform technology, it has developed HS-120 as a potential treatment for NSCLC. It is conducting a Phase II trial of HS-410 in patients with NMIBC, and a Phase Ib trial of HS-110, in combination with nivolumab (Opdivo) to treat patients with NSCLC.
